A 10-Year Evolution of Patient Dosimetry for Lu-177 Dotatate Peptide Receptor Radionuclide Therapy (PRRT)

被引：0
作者：
Ross, Erin [1 ]
Ram, Lydia [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242137
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Practical kidney dosimetry in peptide receptor radionuclide therapy using [177Lu]Lu-DOTATOC and [177Lu]Lu-DOTATATE with focus on uncertainty estimates
    Peter Frøhlich Staanum
    Anders Floor Frellsen
    Marie Louise Olesen
    Peter Iversen
    Anne Kirstine Arveschoug
    EJNMMI Physics, 8
  • [42] Data collection procedures for bone marrow dosimetry in peptide receptor radionuclide therapy with 177Lu-DOTATATE on neuroendocrine tumors
    Frederiksen, M. H. B.
    Klausen, T. L.
    de Nijs, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S631 - S631
  • [43] Patient level dosimetry for radionuclide therapy: proof of concept for patients receiving 177Lu-DOTATATE
    St James, Sara
    Padilla-Morales, Erika
    Bergsland, Emily
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [44] In-vivo stability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
    Wilking, H.
    Ilan, E.
    Sandstrom, M.
    Andersson, C.
    Ost, A.
    Velikyan, I.
    Fross-Baron, K.
    Sundin, A.
    Lubberink, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S592
  • [45] 177Lu-DOTATATE receptor radionuclide therapy: Internal dosimetry estimates and considerations for practical protocols
    Cremonesi, Marta
    Di Dia, Giuseppina Amalia
    Bodei, Lisa
    Botta, Francesca
    Ferrari, Mahila
    De Cicco, Concetta
    Prisco, Gennaro
    Pedroli, Guido
    Paganelli, Giovanni
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [46] Peptide Receptor Radionuclide Therapy (Lu-177 DOTATATE) in Progressive Neuroendocrine Tumors (NETs): Potential Predictors of Progression Free Survival (PFS)
    Badawy, Mohmed
    Johnson, Geoffrey B.
    Hobday, Timothy
    Packard, Annie T.
    Jain, Manoj
    Halfdanarson, Thorvardur R.
    Young, Jason R.
    Thorpe, Matthew P.
    Eiring, Rachel A.
    Kendi, Ayse Tuba
    PANCREAS, 2022, 51 (03) : E42 - E42
  • [47] Targeted Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Alters Joints Inflammation
    Usmani, Sharjeel
    Rasheed, Rashid
    Ahmed, Najeeb
    Omar, Yehia
    Numani, Shah P.
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (02) : e102 - e104
  • [48] Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
    Anna Sundlöv
    Johan Gustafsson
    Gustav Brolin
    Nadja Mortensen
    Rebecca Hermann
    Peter Bernhardt
    Johanna Svensson
    Michael Ljungberg
    Jan Tennvall
    Katarina Sjögreen Gleisner
    EJNMMI Physics, 5
  • [49] Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
    Sierra, Maribel L.
    Agazzi, Alberto
    Bodei, Lisa
    Pacifici, Monica
    Arico, Demetrio
    De Cicco, Concetta
    Quarna, Jessica
    Sansovini, Maddalena
    De Simone, Michele
    Paganelli, Giovanni
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (06) : 659 - 665
  • [50] Survey of Early Adopters of Peptide Receptor Radionuclide Therapy with Lu-177-dotatate in the USA
    Slonimsky, Einat
    Tulchinsky, Mark
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
12345